SOLVE FSHD Invests US$3 Million in Altay Therapeutics

VANCOUVER, B.C., Sept 21, 2022 – SOLVE FSHD, a venture-philanthropy organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment of US$3 million in Altay Therapeutics; a company focused on developing lifesaving therapies by targeting disease-causing transcription factors.

This investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease modifying treatment.

Introducing our partnership with Altay Therapeutics

SOLVE FSHD is changing the course of history for Altay Therapeutics.

Here's what the patient community is saying.

Novel targets and our focus at Altay Therapeutics.

My life's mission has been to follow in my father's footsteps.